Literature DB >> 10903143

Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity.

H Watanabe1, S Tanase, K Nakajou, T Maruyama, U Kragh-Hansen, M Otagiri.   

Abstract

Recombinant wild-type human serum albumin (rHSA), the single-residue mutants R410A, Y411A, Y411S and Y411F and the double mutant R410A/Y411A were produced using a yeast expression system. The recombinant proteins were correctly folded, as they had the same stability towards guanidine hydrochloride and the same CD spectrum as HSA isolated from serum (native HSA). Thus the global structures of the recombinant proteins are probably very similar to that of native HSA. We investigated, by ultrafiltration and CD, the high-affinity binding of two representative site II ligands, namely ketoprofen and diazepam. According to the crystal structure of HSA, the residues Arg-410 and Tyr-411 protrude into the centre of site II (in subdomain 3A), and the binding results showed that the guanidino moiety of Arg-410, the phenolic oxygen and the aromatic ring of Tyr-411 are important for ketoprofen binding. The guanidino moiety probably interacts electrostatically with the carboxy group of ketoprofen, the phenolic oxygen could make a hydrogen-bond with the keto group of the ligand, and the aromatic ring may participate in a specific stacking interaction with one of or both of the aromatic rings of ketoprofen. By contrast, Arg-410 is not important for diazepam binding. The two parts of Tyr-411 interact favourably with diazepam, and probably do so in the same way as with ketoprofen. In addition to its unique ligand binding properties, HSA also possesses an esterase-like activity, and studies with p-nitrophenyl acetate as a substrate showed that, although Arg-410 is important, the enzymic activity of HSA is much more dependent on the presence of Tyr-411. A minor activity could be registered when serine, but not alanine or phenylalanine, was present at position 411.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903143      PMCID: PMC1221209          DOI: 10.1042/bj3490813

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Atomic structure and chemistry of human serum albumin.

Authors:  X M He; D C Carter
Journal:  Nature       Date:  1992-07-16       Impact factor: 49.962

2.  Characterization of the benzodiazepine binding site (diazepam site) on human serum albumin.

Authors:  K Maruyama; H Nishigori; M Iwatsuru
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-11       Impact factor: 1.645

3.  The reactivity of p-nitrophenyl acetate with serum albumins.

Authors:  A Awad-Elkarim; G E Means
Journal:  Comp Biochem Physiol B       Date:  1988

Review 4.  Molecular aspects of ligand binding to serum albumin.

Authors:  U Kragh-Hansen
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

5.  Effects of drug binding on the esterase activity of human serum albumin: inhibition modes and binding sites of anionic drugs.

Authors:  Y Ozeki; Y Kurono; T Yotsuyanagi; K Ikeda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1980-02       Impact factor: 1.645

6.  Engineering of the hydrophobic segment of the signal sequence for efficient secretion of human lysozyme by Saccharomyces cerevisiae.

Authors:  Y Yamamoto; Y Taniyama; M Kikuchi; M Ikehara
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

7.  Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4.

Authors:  P P Minghetti; D E Ruffner; W J Kuang; O E Dennison; J W Hawkins; W G Beattie; A Dugaiczyk
Journal:  J Biol Chem       Date:  1986-05-25       Impact factor: 5.157

8.  Binding of suprofen to human serum albumin. Role of the suprofen carboxyl group.

Authors:  T Maruyama; C C Lin; K Yamasaki; T Miyoshi; T Imai; M Yamasaki; M Otagiri
Journal:  Biochem Pharmacol       Date:  1993-03-09       Impact factor: 5.858

9.  Esterase-like activity of human serum albumin. VIII. Reaction with amino acid p-nitrophenyl esters.

Authors:  Y Kurono; I Kushida; H Tanaka; K Ikeda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-08       Impact factor: 1.645

10.  Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations.

Authors:  U Kragh-Hansen; S O Brennan; M Galliano; O Sugita
Journal:  Mol Pharmacol       Date:  1990-02       Impact factor: 4.436

View more
  39 in total

1.  Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants.

Authors:  H Watanabe; U Kragh-Hansen; S Tanase; K Nakajou; M Mitarai; Y Iwao; T Maruyama; M Otagiri
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 2.  Pharmaceutical strategies utilizing recombinant human serum albumin.

Authors:  Victor Tuan Giam Chuang; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

3.  Prediction of plasma protein binding of drugs using Kier-Hall valence connectivity indices and 4D-fingerprint molecular similarity analyses.

Authors:  Jianzhong Liu; Liu Yang; Yi Li; Dahua Pan; Anton J Hopfinger
Journal:  J Comput Aided Mol Des       Date:  2005-11-03       Impact factor: 3.686

4.  Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.

Authors:  Joonyoung Park; Bo Sun; Yoon Yeo
Journal:  J Control Release       Date:  2016-12-31       Impact factor: 9.776

5.  Modulated Protein Binding Ability of Anti-Diabetic Drugs in Presence of Monodispersed Gold Nanoparticles and its Inhibitory Potential towards Advanced Glycated End (AGE) Product Formation.

Authors:  Imocha Rajkumar Singh; Sivaprasad Mitra
Journal:  J Fluoresc       Date:  2020-01-10       Impact factor: 2.217

6.  Bioactivity of albumins bound to silver nanoparticles.

Authors:  Jessy Mariam; S Sivakami; D C Kothari; P M Dongre
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

7.  Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo.

Authors:  Makoto Anraku; Ulrich Kragh-Hansen; Keiichi Kawai; Toru Maruyama; Yasuomi Yamasaki; Yoshinobu Takakura; Masaki Otagiri
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

8.  Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation.

Authors:  Jinyu Li; Xiaolei Zhu; Cao Yang; Rongwei Shi
Journal:  J Mol Model       Date:  2009-11-12       Impact factor: 1.810

9.  Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545.

Authors:  Mariya S Liyasova; Lawrence M Schopfer; Oksana Lockridge
Journal:  Biochem Pharmacol       Date:  2009-10-27       Impact factor: 5.858

10.  Binding of lipoic acid induces conformational change and appearance of a new binding site in methylglyoxal modified serum albumin.

Authors:  George Suji; Santosh A Khedkar; Sreelekha K Singh; Nand Kishore; Evans C Coutinho; Vikrant M Bhor; S Sivakami
Journal:  Protein J       Date:  2008-06       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.